Skip to main content
Top
Published in: BMC Primary Care 1/2020

Open Access 01-12-2020 | Esomeprazole | Research article

Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia

Authors: Jianyun Wu, Scott Dickinson, Zain Elgebaly, Suzanne Blogg, Aine Heaney, Yien Soo, Benjamin Daniels, Lynn Weekes

Published in: BMC Primary Care | Issue 1/2020

Login to get access

Abstract

Background

This study evaluated the impact of multifaceted NPS MedicineWise programs that targeted all general practitioners (GPs) in Australia in 2009 and 2015 with the aim of reducing unnecessary prescribing of proton pump inhibitors (PPIs) and encouraged stepping down to a lower strength PPI or to discontinue treatment. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the Royal Australian College of General Practitioners (RACGP).

Methods

Outcome measures included monthly dispensing rates of different strength PPIs prescribed by GPs to concessional patients in Australia. All PPIs were categorized according to the May 2019 revised classifications for standard and low strength PPIs except for esomeprazole 40 mg which was classified as a standard strength and esomeprazole 20 mg as low strength for this analysis. Time series analyses was conducted of the dispensing rates of PPI prescriptions for concessional patients between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016.

Results

Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs for concessional patients between April 2006 and March 2015, and an 8.6% reduction between April 2009 and June 2016 following the 2015 program launch. We observed a significant increase of 5.6% in the dispensing rate of low strength PPIs for concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program.

Conclusions

The NPS MedicineWise programs were associated with reductions in the dispensing rate of standard strength PPIs by June 2016 and an increase in the dispensing rate of low-strength PPIs by March 2015 although this trend did not continue following the 2015 program. This suggests that GPs are stepping down patients to lower strength PPIs following the educational programs. However, lower strength PPIs are still not the majority of PPIs dispensed in Australian and regular interventions to sustain and improve PPI management by GPs may be warranted.
Literature
4.
go back to reference Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5:337–44.CrossRef Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5:337–44.CrossRef
5.
go back to reference Gracie DJ, Ford AC. The possible risks of proton pump inhibitors. Med J Aust. 2016;205:292–3.CrossRef Gracie DJ, Ford AC. The possible risks of proton pump inhibitors. Med J Aust. 2016;205:292–3.CrossRef
6.
go back to reference Roughead EE, Chan EW, Choi NK, et al. Proton pump inhibitors and risk of Clostridium difficile infection: a multi-country study using sequence symmetry analysis. Expert Opin Drug Saf. 2016;15:1589–95.CrossRef Roughead EE, Chan EW, Choi NK, et al. Proton pump inhibitors and risk of Clostridium difficile infection: a multi-country study using sequence symmetry analysis. Expert Opin Drug Saf. 2016;15:1589–95.CrossRef
7.
go back to reference Therapeutic Goods Administration. Proton pump inhibitors and acute interstitial nephritis Canberra. In: Australian Government Department of Health and Ageing; 2011. Therapeutic Goods Administration. Proton pump inhibitors and acute interstitial nephritis Canberra. In: Australian Government Department of Health and Ageing; 2011.
8.
go back to reference Xie Y, Bowe B, Li T, et al. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7:e015735.CrossRef Xie Y, Bowe B, Li T, et al. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7:e015735.CrossRef
9.
go back to reference Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115–27.CrossRef Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115–27.CrossRef
10.
go back to reference Yadlapati R, Kahrilas PJ. When is proton pump inhibitor use appropriate? BMC Med. 2017;15:36.CrossRef Yadlapati R, Kahrilas PJ. When is proton pump inhibitor use appropriate? BMC Med. 2017;15:36.CrossRef
11.
go back to reference Ahrens D, Behrens G, Himmel W, Kochen MM, Chenot J-F. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract. 2012;66:767–73.CrossRef Ahrens D, Behrens G, Himmel W, Kochen MM, Chenot J-F. Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care. Int J Clin Pract. 2012;66:767–73.CrossRef
12.
go back to reference Kelly OB, Dillane C, Patchett SE, Harewood GC, Murray FE. The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study. Dig Dis Sci. 2015;60:2280–6.CrossRef Kelly OB, Dillane C, Patchett SE, Harewood GC, Murray FE. The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study. Dig Dis Sci. 2015;60:2280–6.CrossRef
13.
go back to reference Batuwitage BT, Kingham JGC, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83:66–8.CrossRef Batuwitage BT, Kingham JGC, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83:66–8.CrossRef
15.
go back to reference Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010;19:1019–24.CrossRef Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010;19:1019–24.CrossRef
21.
go back to reference MedicineWise NPS. National Consumer Survey: audience insights report. Sydney: NPS MedicineWise; 2017. MedicineWise NPS. National Consumer Survey: audience insights report. Sydney: NPS MedicineWise; 2017.
23.
go back to reference Mellish L, Karanges EA, Litchfield MJ, et al. The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers. BMC Research Notes. 2015;8:634.CrossRef Mellish L, Karanges EA, Litchfield MJ, et al. The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers. BMC Research Notes. 2015;8:634.CrossRef
24.
go back to reference Mandryk JA, Mackson JM, Horn FE, et al. Measuring change in prescription drug utilization in Australia. Pharmacoepidemiol Drug Saf. 2006;15:477–84.CrossRef Mandryk JA, Mackson JM, Horn FE, et al. Measuring change in prescription drug utilization in Australia. Pharmacoepidemiol Drug Saf. 2006;15:477–84.CrossRef
25.
go back to reference Horn FE, Mandryk JA, Mackson JM, et al. Measurement of changes in antihypertensive drug utilisation following primary care educational interventions. Pharmacoepidemiol Drug Saf. 2007;16:297–308.CrossRef Horn FE, Mandryk JA, Mackson JM, et al. Measurement of changes in antihypertensive drug utilisation following primary care educational interventions. Pharmacoepidemiol Drug Saf. 2007;16:297–308.CrossRef
26.
go back to reference Wood S. Mgcv: mixed GAM computation vehicle with automatic smoothness estimation. R package version 1; 2017. p. 8–22. <URL: https://CRAN.R-project.org/package=mgcv>. Wood S. Mgcv: mixed GAM computation vehicle with automatic smoothness estimation. R package version 1; 2017. p. 8–22. <URL: https://​CRAN.​R-project.​org/​package=​mgcv>.​
27.
go back to reference Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team. _nlme: Linear and Nonlinear Mixed Effects Models_. R package version 3; 2017. p. 1–131. <URL: https://CRAN.R-project.org/package=nlme>. Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team. _nlme: Linear and Nonlinear Mixed Effects Models_. R package version 3; 2017. p. 1–131. <URL: https://​CRAN.​R-project.​org/​package=​nlme>.​
28.
go back to reference Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2017. Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2017.
29.
go back to reference Pratt NL, Kalisch Ellett LM, Sluggett JK, et al. Use of proton pump inhibitors among older Australians: national quality improvement programmes have led to sustained practice change. Int J Qual Health Care. 2017;29:75–82.CrossRef Pratt NL, Kalisch Ellett LM, Sluggett JK, et al. Use of proton pump inhibitors among older Australians: national quality improvement programmes have led to sustained practice change. Int J Qual Health Care. 2017;29:75–82.CrossRef
30.
go back to reference May F, Rowett D, Gilbert A, McNeece J. Outcomes of an educational-outreach service for community medical practitioners: non-steroidal anti-inflammatory drugs. Med J Aust. 1999;170. May F, Rowett D, Gilbert A, McNeece J. Outcomes of an educational-outreach service for community medical practitioners: non-steroidal anti-inflammatory drugs. Med J Aust. 1999;170.
31.
go back to reference Szonyi G, Millard R. Controlled trial evaluation of a general practitioner education package on incontinence: use of a mailed questionnaire. Br J Urol. 1994;76:615–20.CrossRef Szonyi G, Millard R. Controlled trial evaluation of a general practitioner education package on incontinence: use of a mailed questionnaire. Br J Urol. 1994;76:615–20.CrossRef
32.
go back to reference Kerse N, Flicker L, Jolley D, Arroll B. D Y: improving the health behaviours of elderly people: a randomized controlled trial of a general practice education programme. BMJ. 1999;319:683.CrossRef Kerse N, Flicker L, Jolley D, Arroll B. D Y: improving the health behaviours of elderly people: a randomized controlled trial of a general practice education programme. BMJ. 1999;319:683.CrossRef
33.
go back to reference Sanci L, Coffey C, Veit F, et al. Evaluation of the effectiveness of an educational intervention for general practitioners in adolescent health care: randomized controlled trial. BMJ. 2000;320:224.CrossRef Sanci L, Coffey C, Veit F, et al. Evaluation of the effectiveness of an educational intervention for general practitioners in adolescent health care: randomized controlled trial. BMJ. 2000;320:224.CrossRef
Metadata
Title
Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia
Authors
Jianyun Wu
Scott Dickinson
Zain Elgebaly
Suzanne Blogg
Aine Heaney
Yien Soo
Benjamin Daniels
Lynn Weekes
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Primary Care / Issue 1/2020
Electronic ISSN: 2731-4553
DOI
https://doi.org/10.1186/s12875-020-01158-1

Other articles of this Issue 1/2020

BMC Primary Care 1/2020 Go to the issue